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ABSTRACT 
 
Objective: To test the hypothesis that anti-drug antibodies against alemtuzumab could become 
relevant after repeated treatments for some individuals, possibly explaining occasional treatment 
resistance. 
Methods: Recombinant alemtuzumab single-chain variable fragment antibody with a dual tandem 
nanoluciferase reporter linker was made and used to detect binding anti-drug antibodies. 
Alemtuzumab IgG Alexa-Fluor 488 conjugate was used in a competitive-binding cell based assay to 
detect neutralizing anti-drug antibodies. The assays were used to retrospectively screen, blinded, 
banked-serum samples from people with multiple sclerosis (n=32) who had received three or more 
cycles of alemtuzumab. Lymphocyte depletion was measured between baseline and about 1 month 
post-infusion. 
Results: The number of individuals showing limited depletion of lymphocytes increased with the 
number of treatment cycles. Lack of depletion was also a poor prognostic feature for future disease 
activity. Anti-drug antibody responses were detected in 29/32 (90.6%) individuals. Neutralizing 
antibodies occurred prior to the development of limited depletion in 6/7 individuals (18.8% of the 
whole sample). Pre-infusion, anti-drug antibody levels predicted limited, post-infusion lymphocyte 
depletion. 
Conclusions: Although anti-drug antibodies to alemtuzumab have been portrayed as being of no 
clinical significance, alemtuzumab-specific antibodies appear to be clinically relevant for some 
individuals, although causation remains to be established. Monitoring of, lymphocyte depletion and 
the anti-drug response may be of practical value in patients requiring additional cycles of 
alemtuzumab. Anti-drug antibody detection may help to inform on re-treatment or switching to 
another treatment.  
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INTRODUCTION 
Multiple sclerosis (MS) is an immune-mediated, demyelinating disease of the central nervous system. 
Memory T and B lymphocytes are key in the pathophysiology of MS, and these cell types are targeted 
by an increasing number of disease modifying treatments (DMTs) capable of inhibiting relapsing MS. 
These DMTs are administered continuously or given as a pulsed immune-reconstitution therapy to 
produce long-term disease inhibition[1]. Alemtuzumab was the first biological immune-reconstitution 
therapy licensed for the treatment of people with MS (PwMS)[1, 2]. This depletes lymphocytes in 
vivo and in vitro by a number of mechanisms, including complement fixation and antibody-
dependent cellular cytotoxicity[1, 2], and has been shown to be highly efficacious in suppressing 
relapses in PwMS (CARE MS I and II)[3, 4]. However, a small number of people appear to be 
unresponsive to alemtuzumab and continue to experience clinical relapses despite treatment[5].  
 
Although alemtuzumab was the first humanized monoclonal antibody engineered with the aim of 
reducing immunogenicity to the founding rodent molecule[6], surprisingly, it is one of the most 
immunogenic therapeutic proteins[7, 8] generating anti-drug antibodies (ADA) which may be either 
binding or neutralizing[8]. Yet, these have been reported to be of minimal clinical significance[9-11]. 
Indeed, the dosing schedule of alemtuzumab[9-12] avoids issues of ADA, which occur with high 
frequency (~85%) within 2 years of treatment[13-15]. Using the currently recommended treatment 
schedule, the infusion cycle ends before primary and secondary antibody responses will be 
generated, and the recommended interval of at least 12 months between treatment cycles allows 
ADA levels to subside[7, 13]. Neutralizing ADA, were not mentioned in the pivotal trial reports[10-
12]. These only occurred in 0.6% of PwMS prior to the second infusion cycle[7], so would be 
infrequently problematic within the original two-year treatment cohort[1, 10, 11]. However, as 
additional treatment cycles were shown to be efficacious in people not adequately responding to two 
cycles[3, 4, 15], the European Medicines Agency supported the use of third and fourth treatment 
cycles in 2017. However, pre-dose binding and neutralizing ADA become far more prevalent following 
the second treatment cycle (75% and 31% at 24 months respectively), a factor which may limit the 
biological and clinical efficacy of the subsequent treatment cycles[7, 8]. In this study, we investigated 
the hypothesis that ADA become increasingly problematic after successive cycles of alemtuzumab 
treatment and that the ADA levels may be associated with diminished treatment effectiveness. 
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METHODS 
Anti-drug antibody assays: In order to monitor PwMS in our care, we developed an in-house 
luminescence based, anti-globulin detection assays for binding anti-alemtuzumab-specific 
antibodies[16]. In brief, a recombinant single chain variable fragment based on alemtuzumab variable 
heavy and light chains was engineered as a fusion protein with two nanoluciferase reporter domains 
(GloBody). In the presence of ADA, GloBody-ADA complexes form which are captured on immobilised 
protein-G and the retained luciferase activity measured[16]. Additionally, competitive binding of 
Alexa Fluor 488-labelled alemtuzumab to adherent human CD52-expressing Chinese hamster ovary 
cells, coupled with serial dilutions of serum, was used as a neutralizing assay[17]. Detailed 
methodology has been reported previously[16, 17]. 
 
Ethical approval: Samples were collected with informed consent and ethical approval (Research 
Ethics Committee approval references: 19/WA/0058 and 05/WSE01/11). 
 
Alemtuzumab treatment. People received five daily 12mg infusions at baseline and three daily 
12mg infusions where administered twelve months later[11]. Following disease activity (typically ⩾1 relapse and/or ⩾2 unique lesions defined as either new/enlarging T2 hyper-intense and/or 
gadolinium-enhancing brain and/or spinal cord lesions via magnetic resonance imaging), 
additional cycles of three daily 12 mg infusions could be administered at least 12 months apart[3, 4].  
 
Samples: The assays were applied to bioarchived serum samples from 32 PwMS who had all received 
three or more cycles of alemtuzumab[5]. Samples were obtained from the Welsh Neuroscience 
Research Tissue Bank (WNRTB) and had been donated as part of a long-running population study of 
MS, which has previously been described[18]. Analysis of ADA was performed blinded to clinical and 
laboratory data from the WNRTB. Individuals had received either three (n=24), four (n=3), five (n=4) 
or six (n=1) cycles of alemtuzumab. Absolute lymphocyte counts, taken from routine laboratory 
reports where available, from time points immediately before, and 1-2 month after each infusion 
were used to calculate relative depletion rates. Apparent lymphocyte depletion was defined as ≥ 35% 
reduction in absolute lymphocyte count pre- to post infusion and/or depletion below the lower limit 
of normal.  
 
Statistical analysis: Statistical analysis was performed using t test/Mann Whitney U tests using 
Sigmaplot Software (Systat. San Jose, California, USA). 
 
Data sharing statement: Anonymous data is available on request.  
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RESULTS 
Cohort characteristics. At the time of sample requisition from the WNRTB, 137 people had received 
alemtuzumab within the South Wales cohort. In total, 40 people had received three or more 
treatment cycles of alemtuzumab. The rates of receiving a third (or subsequent treatment) in this 
cohort was 49% (39/80) of people followed up to 5 years and 50% (15/30) of people followed up to 
10 years. Archived blood samples were available from 32 out of the total 40 individuals who had ever 
received a third cycle of treatment. The 32 people who had donated blood samples were 28 female 
(88%), and had a mean age at MS onset of 29 years (range 10 – 44). All PwMS received alemtuzumab 
as first-line treatment; the first cycle was administered after a mean duration of 4.5 years (range 0.6 
– 17) from symptom onset. 
 
Individuals do not deplete lymphocytes on repeated infusion of alemtuzumab. Lymphocyte 
depletion data was available for 32 out of 32 (cycle 1), 32 out 32 (cycle 2), and 31 out of 32 (cycle 3). 
At the population level, lymphocyte depletion was marked and significant (P<0.001) compared to pre-
cycle treatment levels for cycle 1 to cycle 3, (Figure 1). However, at an individual level 31 out of 32 
people (97%) showed apparent lymphocyte depletion following cycle 1, 30 out of 32 (94%) after cycle 
2, 27/31 (87%) after cycle 3 in PwMS (Figure 1). Of the 4 people who did not show apparent 
lymphocyte depletion after cycle 3, two had previously shown limited depletion after cycle 2. 
Lymphocyte subset analysis was not available. Whilst it is recognized that these counts will reflect 
a composite of depleted and repopulating cells[7], whose composition may change due to the 
different reconstitution kinetics of distinct lymphocyte subsets[7], relative lack of depletion may 
be an indicator for the lack of efficacy of alemtuzumab, due to antibody neutralization.   
 
Anti-drug antibody responses occur with high frequency. Baseline serum samples were available for 
17/32 PwMS. Using a binding ADA assay[16], low titres 751 ±1,399 Lux were evident in subjects prior 
to first infusion (Figure 2). However, 29/32 (90.6%) people generated binding ADA with a titre > two 
standard deviations above the baseline mean (> 3,549 Lux) during their subsequent follow up (Figure 
2). Some people demonstrated very high ADA titres (mean 1,288,805 ± 2,773,146 Lux with a range 
1,296-9,965,386 Lux) following alemtuzumab treatment (Figure 2, Figure 4). A standard monoclonal 
anti-alemtuzumab IgG (Bio-Rad HCA-199) spiked into controls serum at ~50 μg/mL generated a signal 
of 21,159 ± 6,468 Lux. The maximum blood concentration range of alemtuzumab immediately after 
the third infusion is 2.3 ± 0.8 μg/mL[14], ADA values in the range of the spiked standard would be 
theoretically at least 16-fold molar excess of the circulating levels of the drug.  
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Relationship between lymphocyte depletion, ADA and treatment response. ADA were clearly 
present in 6/7 individuals before poor depletion occurred. Binding ADA titres were boosted with each  
cycle of treatment and the binding ADA became persistent in some individuals (Figure 3a-d). This was 
associated with increasing levels of antibody neutralization (Figure 3a-d). One individual appeared to 
demonstrate limited lymphocyte depletion in spite of an absence of neutralizing ADA (Figure 3e). 
However, in this case month-1 post infusion lymphocyte data was unavailable. Lymphocyte levels 
were first measured more than 2.5 months post-infusion, so we cannot exclude the possibility that 
depletion, followed by rapid repletion, occurred within this time window. Six of seven individuals who 
depleted poorly, exhibited disease activity within 2 years of infusion. In contrast, it was evident that 
only 13/28 PwMS with apparent lymphocyte depletion demonstrated disease activity after 3 
cycles, with 14/16 people without disease activity having >5years follow-up. People receiving 4 
cycles (Figure 3. n=7/7) of alemtuzumab subsequently exhibited disease activity in this cohort. 
This study was not designed to monitor the clinical significance of antibody neutralization. 
However, when comparing baseline and 5 year EDSS, those who neutralised the alemtuzumab 
response after 3 cycles of treatment, showed a median 1.0 point EDSS worsening (Range 0.5-
2.0. n=5), while those who did not develop neutralizing antibodies showed a median improvement 
of 0.5 EDSS points (range -2.0-2.5. n=26). This may suggest that antibody neutralization has 
clinical significance, but further studies are warranted.  
 
Pre-dose ADA responses may detect subsequent lymphocyte depletion responses. As it is known that 
most people generate ADA that wanes over time (Figure 3B-D)[7, 8, 14], pre-cycle ADA levels and the 
subsequent lymphocyte depletion level will be most informative on the significance of ADA[8]7. 
However, only 23 serum samples from 19 different individuals with lymphocyte depletion data were 
taken less than 2 months before infusion. This included five pre-dose samples from poor-depleting 
individuals whose ADA titres were: 2.7 x 104, 2.8 x 104, 8.9 x104, 1.2 x 105 and 1.0 x106 Lux units (Figure 
3). Many people who depleted lymphocytes exhibited low titre (Below 1.5 x 103 Lux units) antibody 
responses (Figure 4A), however there were individuals that had relatively high titres (5.8 x 104 and 
1.1 x 105 Lux units) of binding ADA but exhibited notable depletion (1.4 to 0.2, 1.8 to 0.4 cells 109/L. 
Figure 4A) and did not relapse for at least 4 and 7 years after infusion. However, these individuals did 
not exhibit neutralizing potential (Figure 4B, 4C). Therefore, binding (<15,000 Lux) and neutralizing 
(≥10 titre for virtually complete neutralization) titres perhaps could be adopted to suggest poor-
depleters and depleters (Figure 4A). It remains to be established if this can be applied prospectively, 
but the data suggests that it is possible that pre-dose ADA titre limits may be set that can exclude 
potential futile treatments. 
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DISCUSSION 
Alemtuzumab is a potent immune reconstitution therapy however, up to 40-50% of people receiving 
alemtuzumab for MS require three or more cycles of treatment[5, 15]. Third and subsequent cycles 
are often followed by a sustained remission of disease activity[4, 15], but cases are recognised to 
occur where people are unresponsive to alemtuzumab and continue to experience clinical relapses 
despite treatment. During the clinical development of alemtuzumab the impact of neutralizing 
antibodies was not mentioned and ADA have been repeatedly portrayed as being clinically 
insignificant[11, 12, 19].  
However, our study suggests that some people develop persistent neutralizing antibody responses to 
alemtuzumab, and that this is associated with limited lymphocyte depletion and disease activity. 
Although, it is not possible to prove cause and effect, it seems likely that high-titre neutralizing 
responses would blunt or inhibit the lymphocyte depletion response. In this study 6/32 (18.8%) 
developed high titres of both binding and neutralizing ADA and showed subsequent evidence of 
relative lack of lymphocyte depletion. This is aligned with other reports in the literature of disease 
activity requiring further infusions associated with lack of lymphocyte depletion, which prompts 
switching to another DMT[20]. However, there are alternative explanations to explain poor depletion 
and disease breakthrough, such as alemtuzumab treatment leading to the emergence of CD52-
negative lymphocytes[21, 22]. This may have contributed to poor depletion despite limited ADA 
response in one individual. Furthermore, pharmacogenomics, such as Fc receptor genetic variants, 
linking to antibody-dependent cellular cytotoxicity, may also be relevant, particularly if antibody titres 
become limiting[1, 23-25].  
 
Although the precise molecular mechanisms that cause the formation of ADA remain to be defined, 
it is evident that the majority of people produce CD52-specific ADA following alemtuzumab 
infusion[7, 13].  This probably relates to a number of factors that include the: dose, dosing 
schedule, biology of alemtuzumab, CD52 expression profile and the repopulation kinetics of ADA 
forming cells and CD52-expressing regulatory subsets[26].  These ADA are boosted with an 
increasing number of infusions, such that they become relatively persistent in some individuals[7, 
13]. Further prospectively collected data may help to validate and extend our findings and identify 
the important perturbations of the immune networks that facilitate ADA formation[7]. 
Importantly, re-evaluation of samples and data from CARE-MS and their extension studies[7, 8, 
19], which contains immunophenotyping and ADA data[7], may provide further valuable insights 
into the relationship between both binding and neutralizing (inhibitory) antibody titres and the 
associated laboratory/clinical data. This may be particularly enhanced if events within lymphoid 
tissues can be also monitored, as they are the probably the source of ADA forming cells and are 
likely to deplete and repopulate differently to the peripheral blood[27, 28]. Previous reports of a 
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lack of association between ADA and lymphocyte depletion at the population level[10, 12, 15] is 
misleading, since population analyses are insensitive to low frequency events, as demonstrated here. 
The influence of neutralizing ADA alone has yet to be reported from the pivotal trial extension data, 
but people with the highest quartile of pre-dose ADA producers, deplete their lymphocytes post-
dose, less efficiently than people in the lower 75% percentile[19], and suggests that analysis of the 
neutralizing response may be informative for treatment response in some individuals. Therefore, the 
neutralizing ADA data from the pivotal trial extension studies, should be reported. Future work may 
also further define levels of ADA that are predictive of disease activity. 
 
The lack of general awareness of the potential of alemtuzumab to induce neutralizing antibodies, 
coupled with the suggestion that disease activity is not related to lymphocyte levels[29] may 
contribute as evidenced by disease activity to viewing lymphocyte depletion data as being 
unimportant. However, a failure of lymphocyte depletion is likely to imply alemtuzumab is less 
effective. Once an individual failed to deplete, this was often seen in subsequent treatment cycles. 
Whilst it will be the case that only a small subset of lymphocytes will be clinically important and these 
will not be accurately monitored by simply measuring lymphocyte numbers, a lack of absolute 
lymphocyte depletion should prompt extra vigilance.   
 
Our study provides important preliminary data that pre-infusion binding ADA titres >15,000 and/or 
complete neutralization at >10 fold dilution, may be associated with poor post-infusion lymphocyte 
depletion. Furthermore, this appears to be a predictor for future disease activity and the need for 
further alemtuzumab infusions. Therefore, monitoring ADA before the second or subsequent infusion 
cycles may be valuable in guiding treatment decisions. The ADA detection technology used here could 
also be applied to other monoclonal antibody treatments, to inform whether to re-treat or to switch 
therapy. Identifying people who are at risk of ineffective treatment responses might save them from 
undergoing an expensive and futile treatment, and ensure cost-effective use of alemtuzumab. 
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Figure Legends 
Figure 1. Lymphocyte depletion following alemtuzumab treatment. People with MS received three 
cycles (n=31). Few of these individuals received four cycles (n=7) cycles of alemtuzumab. The figures 
represent the mean and standard deviation of absolute peripheral blood lymphocyte count and the 
individual levels before and after treatment for each treatment cycle. Those with depletion that 
perhaps suggests atypical/insufficient (low change or absolute depletion level above the lower limit 
of normal) depletion (red), compared to those depleting (grey) are indicated. In some individuals (*) 
post-dose blood counts were more than 2 months from infusion. Statistical analysis was performed 
using t test/Mann Whitney U tests. 
Figure 2. High titre ADA develop in most people following alemtuzumab treatment. Alemtuzumab 
globody was used to detect binding ADA in sera from PwMS who had received alemtuzumab. The 
results show individual baseline responses prior to the initial infusion (n=17), the response to a 
50μg/mL alemtuzumab ADA monoclonal antibody standard (Bio-Rad HCA-199, n=32) and the highest 
titre for each individual (n=32), in any of 4-6 samples/individual banked during treatment. The mean 
± standard deviation group scores are shown. 
Figure 3. Alemtuzumab neutralizing responses appear before PwMS apparently fail to deplete 
lymphocytes. The (A-E) binding and (a-e) neutralizing responses of five individuals treated with 
alemtuzumab. (A-E) The results show the time of the beginning of each alemtuzumab infusion cycle, 
the absolute lymphocyte numbers and the binding ADA titre or the neutralizing responses. A-E Lower 
limit of normal of lymphocyte number (dashed line). In a-e, samples 1-6 or 1-4 are from the same 
individual at sequential time points during follow-up. Year 0 indicates 1 January of the year of the 
initial dosing and the time of treatments and sampling during the year are indicated. 
Figure 4. Alemtuzumab binding and neutralizing responses in people treated with alemtuzumab to 
predict treatment response. Alemtuzumab globody and alemtuzumab Alexa Fluor 488 conjugates 
were used to detect (A) a combination of binding and neutralizing ADA or (B-D) neutralizing ADA in 
sera from PwMS who had received alemtuzumab. (A) The binding ADA response in individual samples 
taken within 2 months before infusion and the level of lymphocyte depletion within 2 months post-
infusion compared to the pre-infusion level, from cycles 1-4. The neutralizing response was tested in 
individuals with a binding ADA level >15,000 lux (red and blue). Those with a titre above a 1:10 serum 
dilution that essentially completely neutralised the alemtuzumab Alexa Fluor 488 binding response 
are indicated (red). Poor depleters were classified, prior to analysis, as those exhibiting less than a 0.4 
x 109 cells/L depletion. Individuals with high titre binding ADA who depleted peripheral blood 
lymphocytes (Blue), were found (B, C) to lack notable neutralizing ADA responses, seen in individuals 
exhibiting poor depletion (Red. 4D).  
